FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225247538> ?p ?o ?g. }

• W4225247538 abstract "You have accessJournal of UrologyCME1 May 2022MP27-19 COMPARATIVE OUT-OF-POCKET COSTS OF TREATMENT OPTIONS IN PRIVATELY INSURED PATIENTS WITH ADVANCED PROSTATE CANCER Daniel D. Joyce, Vidit Sharma, David H. Jiang, Holly K. Van Houten, Lindsey R. Sangaralingham, Eugene D. Kwon, David F. Penson, Stacie B. Dusetzina, Jon C. Tilburt, and Stephen A. Boorjian Daniel D. JoyceDaniel D. Joyce More articles by this author , Vidit SharmaVidit Sharma More articles by this author , David H. JiangDavid H. Jiang More articles by this author , Holly K. Van HoutenHolly K. Van Houten More articles by this author , Lindsey R. SangaralinghamLindsey R. Sangaralingham More articles by this author , Eugene D. KwonEugene D. Kwon More articles by this author , David F. PensonDavid F. Penson More articles by this author , Stacie B. DusetzinaStacie B. Dusetzina More articles by this author , Jon C. TilburtJon C. Tilburt More articles by this author , and Stephen A. BoorjianStephen A. Boorjian More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002570.19AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The out-of-pocket costs (OOPC) associated with treatment options for advanced prostate cancer are understudied. We describe and identify patient level predictors of OOPC associated with advanced prostate cancer treatments. METHODS: Using the OptumLabs claims dataset, we identified all privately insured men with available OOPC receiving systemic therapy for advanced prostate cancer (biochemical recurrent or metastatic) from 2007-2019. Patients were divided into three treatment groups: androgen deprivation (ADT) monotherapy (i.e. leuprolide/degarelix); novel hormonal (abiraterone, enzalutamide, apalutamide, darolutamide); non-hormonal (chemotherapy, immunotherapy). The primary outcome was OOPC in the first year of treatment. Group allocation and patient factors were associated with OOPC using multivariable regressions with generalized linear models with gamma distributions. All costs were adjusted to reflect 2019 U.S. dollars using the consumer price index. RESULTS: In a cohort of 13,661 men, there were 80% (n=10,926) receiving ADT monotherapy, 8% (n=1,084) receiving novel hormonal treatments, and 12% (n=1,651) receiving non-hormonal treatments. Mean OOPC in the first year of treatment were $2,828, $6,882, and $5,191 for ADT monotherapy, novel hormonal, and non-hormonal treatments, respectively (Table). On multivariable analysis, novel hormonal (coeff: 1.99, p<0.001) and non-hormonal (coeff: 1.70, p<0.001) treatments were associated with increased total OOPC in the first year of treatment compared to ADT monotherapy. Patient factors associated (p<0.001) with higher OOPC included: older age, Asian/Hispanic race/ethnicity, and comorbidity. CONCLUSIONS: Patients receiving novel hormonal agents had substantially higher OOPC than other therapies. In addition to raising awareness among prescribers, these data support the inclusion of financial toxicity discussions as a part of patient counseling for these agents. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e457 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Daniel D. Joyce More articles by this author Vidit Sharma More articles by this author David H. Jiang More articles by this author Holly K. Van Houten More articles by this author Lindsey R. Sangaralingham More articles by this author Eugene D. Kwon More articles by this author David F. Penson More articles by this author Stacie B. Dusetzina More articles by this author Jon C. Tilburt More articles by this author Stephen A. Boorjian More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W4225247538 created "2022-05-04" @default.
• W4225247538 creator A5006063761 @default.
• W4225247538 creator A5014688829 @default.
• W4225247538 creator A5025051635 @default.
• W4225247538 creator A5041418355 @default.
• W4225247538 creator A5043501929 @default.
• W4225247538 creator A5048391277 @default.
• W4225247538 creator A5048628138 @default.
• W4225247538 creator A5063867635 @default.
• W4225247538 creator A5063962159 @default.
• W4225247538 creator A5077644150 @default.
• W4225247538 date "2022-05-01" @default.
• W4225247538 modified "2023-09-27" @default.
• W4225247538 title "MP27-19 COMPARATIVE OUT-OF-POCKET COSTS OF TREATMENT OPTIONS IN PRIVATELY INSURED PATIENTS WITH ADVANCED PROSTATE CANCER" @default.
• W4225247538 doi "https://doi.org/10.1097/ju.0000000000002570.19" @default.
• W4225247538 hasPublicationYear "2022" @default.
• W4225247538 type Work @default.
• W4225247538 citedByCount "0" @default.
• W4225247538 crossrefType "journal-article" @default.
• W4225247538 hasAuthorship W4225247538A5006063761 @default.
• W4225247538 hasAuthorship W4225247538A5014688829 @default.
• W4225247538 hasAuthorship W4225247538A5025051635 @default.
• W4225247538 hasAuthorship W4225247538A5041418355 @default.
• W4225247538 hasAuthorship W4225247538A5043501929 @default.
• W4225247538 hasAuthorship W4225247538A5048391277 @default.
• W4225247538 hasAuthorship W4225247538A5048628138 @default.
• W4225247538 hasAuthorship W4225247538A5063867635 @default.
• W4225247538 hasAuthorship W4225247538A5063962159 @default.
• W4225247538 hasAuthorship W4225247538A5077644150 @default.
• W4225247538 hasConcept C121608353 @default.
• W4225247538 hasConcept C126322002 @default.
• W4225247538 hasConcept C143998085 @default.
• W4225247538 hasConcept C2776421732 @default.
• W4225247538 hasConcept C2777899217 @default.
• W4225247538 hasConcept C2778311097 @default.
• W4225247538 hasConcept C2780192828 @default.
• W4225247538 hasConcept C29456083 @default.
• W4225247538 hasConcept C61367390 @default.
• W4225247538 hasConcept C71924100 @default.
• W4225247538 hasConceptScore W4225247538C121608353 @default.
• W4225247538 hasConceptScore W4225247538C126322002 @default.
• W4225247538 hasConceptScore W4225247538C143998085 @default.
• W4225247538 hasConceptScore W4225247538C2776421732 @default.
• W4225247538 hasConceptScore W4225247538C2777899217 @default.
• W4225247538 hasConceptScore W4225247538C2778311097 @default.
• W4225247538 hasConceptScore W4225247538C2780192828 @default.
• W4225247538 hasConceptScore W4225247538C29456083 @default.
• W4225247538 hasConceptScore W4225247538C61367390 @default.
• W4225247538 hasConceptScore W4225247538C71924100 @default.
• W4225247538 hasIssue "Supplement 5" @default.
• W4225247538 hasLocation W42252475381 @default.
• W4225247538 hasOpenAccess W4225247538 @default.
• W4225247538 hasPrimaryLocation W42252475381 @default.
• W4225247538 hasRelatedWork W2162051638 @default.
• W4225247538 hasRelatedWork W2414042649 @default.
• W4225247538 hasRelatedWork W2768688864 @default.
• W4225247538 hasRelatedWork W2791072685 @default.
• W4225247538 hasRelatedWork W2913942481 @default.
• W4225247538 hasRelatedWork W2935114107 @default.
• W4225247538 hasRelatedWork W2982156914 @default.
• W4225247538 hasRelatedWork W2996229517 @default.
• W4225247538 hasRelatedWork W3014214351 @default.
• W4225247538 hasRelatedWork W4297472852 @default.
• W4225247538 hasVolume "207" @default.
• W4225247538 isParatext "false" @default.
• W4225247538 isRetracted "false" @default.
• W4225247538 workType "article" @default.